ArticleDiscover oncology2026
High expression of CD74 is associated with poor prognosis and tumor immune infiltration in Acute Myeloid Leukemia.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the expression patterns of the CD74 gene in Acute Myeloid Leukemia (LAML), its clinical prognostic significance, and its association with the tumor microenvironment (TME).
methodsData from public databases, including TCGA and GTEx, were integrated to analyze the differences in CD74 expression between LAML tissues and normal controls; perform subgroup analysis based on clinical and pathological characteristics; evaluate its prognostic value using survival analysis and ROC curves; elucidate its potential immune regulatory mechanisms through the CIBERSORT algorithm and functional enrichment analysis.
resultsCD74 was significantly overexpressed in LAML tissues, with higher expression observed in the monocyte-derived subtypes (M4-M7) and in patients with high white blood cell counts (P < 0.05). High CD74 expression is significantly associated with poor overall survival in patients with LAML(P < 0.01). Immunohistochemical analysis revealed that CD74 expression was positively correlated with the abundance of memory B cells, monocytes, and M2 macrophages, and was primarily enriched in antigen-presenting and immune response pathways.
conclusionHigh CD74 expression is associated with poor prognosis in patients with LAML and may promote disease progression by reshaping the immune microenvironment; it holds promise as a new prognostic marker and immunotherapy target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.